Overview
Portfolio
More
Infini
Warsaw, Poland
Invests in early‑stage R&D projects with high commercialization potential across chemicals, biotech, nanotech, energy, electronics, cybernetics, mechatronics, B2B IT, aviation, mechanical engineering, and constructio...
Portfolio
13+
Employees
3+
Founded
2014
AUM
≈ $102.0M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
Global
Fund details
Funds
Bridge Alfa
Sources
Infini
Invests in early‑stage R&D projects with high commercialization potential across chemicals, biotech, nanotech, energy, electronics, cybernetics, mechatronics, B2B IT, aviation, mechanical engineering, and construction.
Portfolio
13+
Employees
3+
Founded
2014
AUM
≈ $102.0M
Funds
Bridge Alfa
Showing 2 of 2 matched portfolio companies
Bioceltix develops off-the-shelf biopharmaceuticals utilizing mesenchymal stem cells (MSCs) to create effective treatments for common veterinary conditions. The company addresses the high demand for reliable therapeutic solutions in companion animal care by leveraging the immunomodulatory properties of MSCs and their biologically active substances.
Fresh Inset Vision utilizes patented Vidre+ technology to extend the shelf life of fruits, vegetables, and flowers by gradually releasing an ethylene blocker, which slows down the ripening process. This solution significantly reduces food waste and enhances product quality during storage and transport, benefiting producers, distributors, and consumers alike.
Showing 11 of 11 unmatched portfolio companies